PT - JOURNAL ARTICLE AU - Shibata, Yoko AU - Minemura, Hiroyuki AU - Suzuki, Yasuhito AU - Nikaido, Takefumi AU - Tanino, Yoshinori AU - Fukuhara, Atsuro AU - Kanno, Ryuzo AU - Saito, Hiroyuki AU - Suzuki, Shuzo AU - Ishii, Taeko AU - Inokoshi, Yayoi AU - Sando, Eiichiro AU - Sakuma, Hirofumi AU - Kobayashi, Tatsuho AU - Kume, Hiroaki AU - Kamimoto, Masahiro AU - Aoki, Hideko AU - Takama, Akira AU - Kamiyama, Takamichi AU - Nakayama, Masaru AU - Saito, Kiyoshi AU - Tanigawa, Koichi AU - Sato, Masahiko AU - Kanbe, Toshiyuki AU - Kanzaki, Norio AU - Azuma, Teruhisa AU - Sakamoto, Keiji AU - Nakamura, Yuichi AU - Otani, Hiroshi AU - Waragai, Mitsuru AU - Maeda, Shinsaku AU - Ishida, Tokiya AU - Sugino, Keishi AU - Inage, Minoru AU - Hirama, Noriyuki AU - Furuyama, Kodai AU - Fukushima, Shigeyuki AU - Saito, Hiroshi AU - Machiya, Jun-ichi AU - Machida, Hiroyoshi AU - Abe, Koya AU - Iwabuchi, Katsuyoshi AU - Katagiri, Yuji AU - Aida, Yasuko AU - Abe, Yuki AU - Ota, Takahito AU - Ishizawa, Yuki AU - Tsukada, Yasuhiko AU - Yamada, Ryuki AU - Sato, Riko AU - Omuna, Takumi AU - Tomita, Hikaru AU - Saito, Mikako AU - Watanabe, Natsumi AU - Rikimaru, Mami AU - Kawamata, Takaya AU - Umeda, Takashi AU - Morimoto, Julia AU - Togawa, Ryuichi AU - Sato, Yuki AU - Saito, Junpei AU - Kanazawa, Kenya AU - Omae, Kenji AU - Noriaki, Kurita AU - Iseki, Ken TI - Development and external validation of the DOAT and DOATS scores: simple decision support tools to identify disease progression among nonelderly patients with mild/moderate COVID-19 AID - 10.1101/2021.12.13.21267698 DP - 2021 Jan 01 TA - medRxiv PG - 2021.12.13.21267698 4099 - http://medrxiv.org/content/early/2021/12/14/2021.12.13.21267698.short 4100 - http://medrxiv.org/content/early/2021/12/14/2021.12.13.21267698.full AB - BACKGROUND Due to the dissemination of vaccination against severe acute respiratory syndrome coronavirus 2 in the elderly, the virus-susceptible subjects have shifted to unvaccinated non-elderlies. The risk factors of COVID-19 deterioration in non-elderly patients without respiratory failure have not yet been determined. This study was aimed to create simple predicting method to identify such patients who have high risk for exacerbation.METHODS We analyzed the data of 1,675 patients aged under 65 years who were admitted to hospitals with mild-to-moderate COVID-19. For validation, 324 similar patients were enrolled. Disease progression was defined as administration of medication, oxygen inhalation and mechanical ventilator starting one day or longer after admission.RESULTS The patients who exacerbated tended to be older, male, had histories of smoking, and had high body temperatures, lower oxygen saturation, and comorbidities such as diabetes/obesity and hypertension. Stepwise logistic regression analyses revealed that comorbidities of diabetes/obesity, age ≥ 40 years, body temperature ≥ 38°C, and oxygen saturation < 96% (DOATS) were independent risk factors of worsening COVID-19. As a result two predictive scores were created: DOATS score, which includes all the above risk factors; and DOAT score, which includes all factors except for oxygen saturation. In the original cohort, the areas under the receiver operating characteristic curve of the DOATS and DOAT scores were 0.789 and 0.771, respectively. In the validation, the areas were 0.702 and 0.722, respectively.CONCLUSION We established two simple prediction scores that can quickly evaluate the risk of progression of COVID-19 in non-elderly, mild/moderate patients.Summary The risk stratification models using independent risks, namely comorbidity of diabetes or obesity, age ≥ 40 years, high body temperature ≥ 38□, and oxygen saturation < 96%, DOATS and DOAT scores, predicted worsening COVID-19 in patients with mild-to-moderate cases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Fukushima Medical University gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.AbbreviationsCOVID-19coronavirus disease 2019DOATcomorbidity of diabetes/obesity, age ≥ 40 years, and body temperature ≥ 38°CDOATScomorbidity of diabetes/obesity, age ≥ 40 years, body temperature ≥ 38°C, and oxygen saturation < 96%ECMOextracorporeal membrane oxygenationSARS-CoV-2severe acute respiratory syndrome coronavirus 2